ELITE Launch Expert C. David Green, RPh of Bausch & Lomb, Inc.

C. David Green, RPh

Director of Marketing, Prescription Pharmaceuticals

Bausch & Lomb, Inc., A Valeant Pharmaceuticals North America LLC Company

f3_ELITE_Launch-Expert_C-David-GreenOne-Man Brand Team

Significant sales and marketing achievements are just a few highlights of the powerful industry resume C. David Green, RPh, has built over the past 20 years. But something more distinguishing is “the spirit of collaboration” that David willingly shares with his business partners—combined with a formidable ability to build consensus among internal partners. He is able to focus on what matters to the business, the brand and the people with whom he works to maintain top productivity and deliver extraordinary results—and he does this consistently.

David is, in fact, “a strategic and intelligent marketer who is extremely patient and knowledgeable about his business and category,” says Dora P. Shankman, President & CEO of Shankman Marketing and Media Resources, LLC, who has worked with David on a number of brands. Beyond that, she adds, “Physicians respect him—and his own management team trusts him.”

But his work also speaks for itself. As a specialist in ophthalmology product marketing at Novartis, Valeant Ophthalmics and now Bausch + Lomb, David led multiple brands to success including Visudyne, Timoptic in Ocudose, Lacrisert and Prolensa, which he helped turn into a $60 million brand. Launch expertise is also a strong component of David’s industry resume—and it extends beyond just ophthalmology.

He also played an important role in the launch of multiple groundbreaking medicines, such as Coartem, which has been credited with having made a significant impact on malaria-endemic parts of the world. He launched Coartem in the U.S. as a one-person brand while at Novartis, focusing on getting the brand stocked in American travel clinics and making it available to U.S. Military personnel traveling to countries that still have significant incidence of malaria. And for his tremendous efforts during the launch of Gilenya, the first oral medication approved by the FDA to treat Multiple Sclerosis, David received “The Golden Neuron” award for exhibiting the “Most Grace Under Pressure.”


You May Also Like

My Other Life with Mark Weihmann

PM360 recently spoke to Mark Weihmann, Director, Managed Markets Marketing at Sunovion Pharmaceuticals, about ...